Proximagen Limited has entered into a preclinical biotech partnering agreement with Lundbeck, a big pharma company, to further its research program related to protein kinase inhibitors.
This biotech partnering is part of Upsher-Smith's long-term strategy to advance its current product portfolio of branded drugs.
Specific terms related to the deal have not been disclosed.
For further deal information visit Current Agreements (subscription required)
Read: more on Lundbeck company profile, recent partnering, M&A and financing news and articles
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
Report: Partnering Deals and Alliances with Lundbeck
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity